Type 1 Diabetes Clinical Trial
Official title:
Pilot Study of Closed-Loop Glucose Control in People With Type 1 Diabetes(BPK004)
This study plans to link two existing technologies, the insulin pump and the continuous
glucose monitor (CGM), to essentially develop an artificial pancreas, i.e., closed-loop.
This will be done using two continuous glucose monitors (CGMs), a computer containing an
investigational control algorithm that uses glucose information from the CGM to recommend
insulin dosing, and an insulin pump. The purpose of this study is to test the ability of
continuous glucose monitors together with an insulin pump and a mathematical formula to
control blood sugar levels of people with type 1 diabetes.
The Closed-Loop control algorithm will:
1. Suggest adequate insulin delivery for blood glucose control in steady state
(overnight);
2. Cover adequately with an insulin bolus the pre-set carbohydrate content of a breakfast.
If successful, this study will conceptually prove the feasibility of automated
model-predictive closed-loop glucose control in T1DM.
Each patient had an outpatient screening evaluation, and two 22 h overnight hospital
admissions separated by a 2- to 4-week waiting period. Each inpatient admission began at
15:00 and ended at 13:00 on the following day. Subjects ate dinners and lunches with
carbohydrate content that was the same at admission 1 and admission 2 and had identical
morning meals of Ensure Plus (Abbott Nutrition, Columbus, OH). Two days before each
admission, two Freestyle Navigator CGM devices (Abbott Diabetes Care) continuous glucose
monitors were applied to the patient to allow for stabilization of the sensors and for
assessment of their performance.
During admission 1, open-loop control was used, with the subjects' usual insulin routine and
their personal insulin pump. During admission 2, an OmniPod Insulin Management System
(Insulet Corp.) was inserted and used for closed-loop control of blood glucose. Insulin
lispro (Eli Lilly, Indianapolis, IN), chosen based on commercial assays available, was used
during both inpatient admissions.
At the beginning of admission 2, one of the two CGM devices was designated as primary, and
the closed-loop control algorithm used the data of that system, unless a problem was
detected. At 17:00, the model-predictive control (MPC) was initiated in a data-collection
mode, automatically receiving CGM data every minute. Administration of the predinner insulin
bolus was overseen by the attending physician. MPC, closed-loop control began at 21:30 and
continued until 12:00 the next day for a total of 14.5 h.
Per FDA restrictions, the algorithm did not automatically control the insulin pump. Instead,
the algorithm suggested insulin boluses every 15 min, which, if accepted, were programmed
into the insulin pump by the attending physician. This was done for safety reasons, allowing
the physician to override insulin delivery suggestions at any time. Reference blood glucose
(using a YSI Life Sciences or a Beckman glucose analyzer) was sampled every 30 min. The
protocol required switching to more frequent 15 min reference blood glucose sampling if
hypoglycemia occurred or was imminent. Fast-acting carbohydrate (glucose tablets or fruit
juice) was given when reference blood glucose fell below 3.9 mmol/liter, regardless of the
CGM readings.
;
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05653518 -
Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes
|
N/A | |
Enrolling by invitation |
NCT05515939 -
Evaluating the InPen in Pediatric Type 1 Diabetes
|
||
Completed |
NCT05109520 -
Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
|
||
Recruiting |
NCT04016987 -
Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT04190368 -
Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05413005 -
Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus
|
Early Phase 1 | |
Active, not recruiting |
NCT04668612 -
Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes
|
N/A | |
Completed |
NCT02837094 -
Enhanced Epidermal Antigen Specific Immunotherapy Trial -1
|
Phase 1 | |
Recruiting |
NCT05414409 -
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
|
Phase 2 | |
Recruiting |
NCT05670366 -
The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT05418699 -
Real-life Data From Diabetic Patients on Closed-loop Pumps
|
||
Completed |
NCT04084171 -
Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6
|
N/A | |
Recruiting |
NCT06144554 -
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
|
||
Recruiting |
NCT05379686 -
Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05153070 -
Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes
|
Phase 2 | |
Completed |
NCT05281614 -
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
|
Early Phase 1 | |
Withdrawn |
NCT04259775 -
Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT01600924 -
Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
|
||
Completed |
NCT02750527 -
Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany
|
||
Completed |
NCT02914886 -
Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS)
|
Phase 4 |